Evidence map›Paper›PMID 26892848›Full record

Trial reportThe British journal of psychiatry : the journal of mental science2016

Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.

Jay D Amsterdam, Lorenzo Lorenzo-Luaces, Irene Soeller, Susan Qing Li, Jun J Mao, Robert J DeRubeis

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The British journal of psychiatry : the journal of mental science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2022
    Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Bipolar II Disorder: Understudied and Underdiagnosed.Focus (American Psychiatric Publishing) · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Antidepressants in bipolar depression: an enduring controversy.International journal of bipolar disorders · 2018
    Review
  16. Review
  17. Article
  18. Bipolar Disorder and Population Health.Psychiatric services (Washington, D.C.) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jay D AmsterdamJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA jamsterd@mail.med.upenn.edu.
Lorenzo Lorenzo-LuacesJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Irene SoellerJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Susan Qing LiJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jun J MaoJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert J DeRubeisJay D. Amsterdam, MD, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; Lorenzo Lorenzo-Luaces, MA, Depression Research Unit, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia and Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania; Irene Soeller, MSN, Susan Qing Li, MS, Depression Research Unit, Department of Psychiatry and Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; Jun J. Mao, MD, Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Robert J. DeRubeis, PhD, Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Pennsylvania · US

Funding

Treatment of Bipolar Type II Major DepressionR01MH060353 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI DERUBEIS, ROBERT J · 2001 to 2011
$3.9M
1/2-Prevention of Relapse & Recurrence of Bipolar DepressionR01MH080097 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI DERUBEIS, ROBERT J · 2009 to 2013
$2.0M
NIMH NIH HHS MH060353NIMH NIH HHS MH080097NIMH NIH HHS R01 MH060353NIMH NIH HHS R01 MH080097
6 · The paper itself

Abstract

backgroundControversy exists over antidepressant use in bipolar II depression.

aimsTo compare the safety and effectiveness of antidepressantv.mood stabiliser monotherapy for bipolar type II major depressive episodes.

methodRandomised, double-blind, parallel-group, 12-week comparison of venlafaxine (n= 65)v.lithium (n= 64) monotherapy in adult out-patients (trial registration numberNCT00602537).

resultsPrimary outcome - venlafaxine produced a greater response rate (67.7%)v lithium (34.4%,P<0.001). Secondary outcomes - venlafaxine produced a greater remission rate (58.5%v 28.1%,P<0.001); greater decline in depression symptom scores over time (β = -5.32, s.e. = 1.16, χ(2)= 21.19,P<0.001); greater reduction in global severity scores over time (β = -1.05, s.e. = 0.22, w(2)= 22.33,P<0.001); and greater improvement in global change scores (β = -1.31, s.e. = 0.32, χ(2)= 16.95,P<0.001) relative to lithium. No statistically significant or clinically meaningful differences in hypomanic symptoms were observed between treatments.

conclusionsThese findings suggest that short-term venlafaxine monotherapy may provide effective antidepressant treatment for bipolar II depression without a statistically significant increase in hypomanic symptoms relative to lithium.

Indexed as

AdolescentAdultAgedAntidepressive AgentsBipolar DisorderDouble-Blind MethodFemaleHumansLithium CompoundsMaleMiddle AgedPsychiatric Status Rating ScalesTreatment OutcomeVenlafaxine HydrochlorideYoung AdultAntidepressive AgentsLithium CompoundsVenlafaxine Hydrochloride

Identifiers

PMID26892848
PMCPMC4816972
OpenAlexW2287449015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.